- 1 A Multi-center, Prospective, Observational-cohort controlled study of Clinical Outcomes
- 2 following COVID-19 Convalescent plasma therapy in hospitalized COVID-19 patients
- 3
- 4 Lakshmi Chauhan^{1,2}, Jack Pattee³, Joshay Ford², Chris Thomas ², Kelsey Lesteberg¹,
- 5 Eric Richards⁴, Michele Loi⁵, Larry Dumont^{2,6}, Kyle Annen⁵, Mary Berg⁴, Mercedes
- ⁶ Zirbes⁷, Amanda Miller⁷, Timothy C. Jenkins⁸, Tellen D. Bennett^{5,7,9}, Daniel Monkowski⁴,
- 7 Rebecca S. Boxer¹⁰, and J. David Beckham^{1,2,7}
- 8
- 9 1-Department of Medicine, Division of Infectious Diseases, University of Colorado
- 10 Anschutz Medical Campus, Aurora, CO.
- 11 2-University of Colorado School of Medicine, Aurora, CO.
- 12 3-Center for Innovative Design and Analysis, University of Colorado Anschutz Medical
- 13 Campus, Aurora, CO.
- 14 4-University of Colorado Hospital System, CO.
- 15 5-Children's Hospital Colorado, Aurora, CO.
- 16 6-Vitalant Research Institute, Denver, CO.
- 17 7-Colorado Clinical and Translational Sciences Institute, University of Colorado
- 18 Anschutz Medical Campus, Aurora, CO.
- 19 8-Denver Health Medical Center, Denver, CO.
- 20 10-Department of Pediatrics, Section of Informatics and Data Science, University of
- 21 Colorado Anschutz Medical Campus, Aurora, CO.
- 10-Institute for Health Research, Kaiser Permanente of Colorado, Aurora, CO.
- 23
- 24
- 25 Keywords: COVID-19, convalescent plasma, hospitalization, mortality
- 26
- 27
- 28 Running Title: COVID19 Convalescent Plasma Treatment
- 29
- 30 Correspondence: J. David Beckham MD, Department of Medicine, Division of Infectious
- Diseases, University of Colorado Anschutz Medical Campus, 12800 East 19th Ave
- 32 B8333, Aurora, CO 80045. (<u>David.beckham@cuanschutz.edu</u>).

33

Article's Main Point: A multi-center, prospective cohort-controlled trial of COVID19
 convalescent plasma therapy in hospitalized COVID19 patients did not show benefit in
 time to discharge or inpatient mortality.

37

38 Abstract

39 Background: The SARS-CoV2 pandemic has caused high inpatient mortality and

40 morbidity throughout the world. COVID19 convalescent plasma has been utilized as a

41 potential therapy for patients hospitalized with COVID19 pneumonia. This study

42 evaluated the outcomes of hospitalized COVID19 patients treated with COVID19

43 convalescent plasma in a prospective, observational multicenter trial.

44 <u>Methods:</u> From April 2020 through August 2020, hospitalized COVID19 patients at 16

45 participating hospitals in Colorado were enrolled and treated with COVID19

46 convalescent plasma (CCP) and compared to hospitalized patients with COVID19 who

47 were not treated with convalescent plasma. Plasma antibody levels were determined

following the trial given that antibody tests were not approved at the initiation of the trial.

49 CCP-treated and untreated COVID19 hospitalized patients were matched using

50 propensity scores followed by analysis for length of hospitalization and inpatient

51 mortality.

52 <u>Results:</u> 542 total hospitalized COVID19 patients were enrolled at 16 hospitals across

the region. A total of 468 hospitalized COVID19 patients were entered into propensity

score matching with 188 patients matched for analysis in the CCP-treatment and control

arms. Fine-Gray models revealed increased length of hospital stay in CCP-treated
patients and no change in inpatient mortality compared to controls. In subgroup analysis
of CCP-treated patients within 7 days of admission, there was no difference in length of
hospitalization and inpatient mortality.

59 <u>Conclusions</u>: These data show that treatment of hospitalized COVID19 patients with

60 CCP did not significantly improve patient hospitalization length of stay or inpatient

61 mortality.

62

63 Background:

The ongoing pandemic due to SARS-CoV2 has caused over 150 million cases 64 and 3 million deaths worldwide as of April 2021. Since the onset of the pandemic, 65 various therapeutic measures including antivirals, immunomodulatory therapeutics, and 66 passive antibody therapies have been evaluated for efficacy in the treatment of 67 COVID19. Convalescent plasma therapy has been utilized for several viral and non-viral 68 infectious diseases throughout history and was the only means of treating certain 69 infectious diseases prior to the development of antimicrobial-specific therapy in the 70 1940s.[1, 2] Experience from prior outbreaks with other coronaviruses, such as SARS-71 72 CoV, shows that convalescent plasma contains neutralizing antibodies to the relevant virus and neutralizing antibodies may provide therapeutic benefit to acutely infected 73 patients.[3] In the case of SARS-CoV2, passive antibody therapy with convalescent 74 75 plasma may mediate protection by viral neutralization or other mechanisms such as enhanced phagocytosis and antigen processing of virions. 76

Convalescent plasma, hyper-immune globulin, and monoclonal antibodies are 77 different passive antibody therapeutics evaluated as possible treatments for COVID-19. 78 Recent studies of COVID19 convalescent plasma (CCP) therapy in several studies 79 have shown potential benefit of treatment in hospitalized COVID19 patients.[4-7] Other 80 studies including randomized, open-label trials have exhibited lack of a clear clinical 81 82 benefit from CCP therapy in hospitalized COVID-19 patients.[8-10] Because, each study exhibits a range of strengths and weaknesses in study design, different targeted patient 83 populations, and study power, additional studies of CCP therapy in hospitalized COVID-84 19 patients are needed to inform appropriate use of CCP as a potential therapeutic 85 alternative for COVID19. 86

Our study utilized a multi-center trial design across 16 academic and nonacademic hospitals in Colorado in an open-label, prospective, observational, cohortcontrolled trial to evaluate length of hospitalization and inpatient mortality rate in COVID-19 patients treated with CCP. We found that CCP treatment of hospitalized COVID19 patients did not significantly alter length of hospitalization or inpatient mortality rates. These data support recent findings showing that treatment with CCP for hospitalized COVID19 patients does not significantly improve clinical outcomes.

94 Methods:

This was an open-label, prospective, multi-center cohort trial comparing
hospitalized patients with COVID-19 who received CCP to hospitalized COVID-19
patients who received standard-of-care treatment. The clinical study was conducted at
16 hospitals in Colorado including UCHealth Metro Denver, UCHealth North, UCHealth
South hospitals, Denver Health Medical Center, Children's Hospital of Colorado, and

SCL Health Hospitals. All human clinical trial work on COVID-19 was approved by the 100 Colorado Multi-Institution Review Board (COMIRB, #20-0986, #20-0990) prior to the 101 study opening. All hospitals within networks of UCHealth, Children's Hospital Colorado, 102 and Denver Health Medical Center provided CCP through a University of Colorado 103 Expanded Access program (FDA IND#21426). SCL Health Hospitals provided CCP 104 105 through FDA Expanded Access program sponsored by Mayo Clinic. All patients or designated decision makers provided signed informed consent prior to enrollment into 106 expanded access programs to receive CCP. The study was conducted from April 2020 107 through August 2020. 108

109 Each site prospectively screened eligible patients for inclusion based on predetermined inclusion criteria: age 18 years or older, laboratory confirmed diagnosis of 110 SARS-CoV-2 infection by detection of nucleic acid from a respiratory sample, admission 111 to a participating facility, COVID-19 pulmonary disease requiring hospitalization, 112 113 sufficient COVID19 convalescent plasma available for treatment, and informed consent provided by the patient or healthcare proxy. Exclusion criteria for the observational 114 clinical trial included receipt of pooled immunoglobulin in the past 30 days, patients 115 116 placed on extracorporeal membrane oxygenation, history of transfusion reaction, contra-indication to receiving plasma products, and risk of transfusion exceeds potential 117 benefit based on clinician determination. 118

119 Control patients were identified, and data captured over each month of the study 120 using a UCHealth database of hospitalized COVID19 patients for each month from April 121 through August of 2020. Data was abstracted from all hospitalized COVID-19 patients in 122 the UCHealth system that met the inclusion and exclusion criteria above but did not

receive CCP therapy over the same time period. As previously described, all patient

data was entered and maintained in a secure, HIPAA-compliant REDCap database.[11]

125 Convalescent Plasma procurement and transfusion

FDA approval of the expanded access program for the use of convalescent 126 plasma was obtained (IND#21426). Convalescent plasma was allocated from FDA-127 registered blood establishments (Children's Hospital Colorado, Garth Englund Blood 128 129 Center, Vitalant Center) to the treating hospitals using standardized procedures. COVID-19 convalescent plasma was supplied as an investigational blood product and 130 was administered according to standard hospital procedures for plasma administration. 131 Plasma was infused over 1-2 hours (rate of 100-250 ml/hr). Pre-medications, such as 132 acetaminophen or diphenhydramine were provided as indicated by the treating 133 physician. One unit of COVID-19 convalescent plasma was administered to anyone 134 weighing less than 90 kg and 2 units were given to patients over 90kg. Levels of binding 135 antibodies were assessed using VITROS anti-SARS CoV2 IgG assay. Some CCP units 136 137 were provided prior to availability of antibody testing and frozen samples were each retrospectively tested for antibody. Of 375 units of CCP utilized in the study, 362 met 138 FDA criteria for positive CCP antibody > 12. Three tested units were negative for 139 140 antibody and 10 units were not tested due to lack of frozen sample. The patients that received these units were included in the full intention-to-treat analysis. Ten patients 141 enrolled through SCL Health had CCP units tested through the Mayo Clinic Expanded 142 access program and data was not available for analysis. 143

144 Propensity Score Matching

Propensity score matching was performed to ensure that potential confounding 145 factors were balanced between the CCP treatment group and the control group. 146 Propensity score matching is an analysis approach utilized for non-randomized trials to 147 minimize bias in estimating the treatment effect. [12, 13] Propensity scores are 148 calculated based on baseline criteria at admission that are expected to influence 149 150 outcome. For example, age over 70 years is known to increase risk of a negative outcome for patients hospitalized with COVID19.[14] Thus, matching patients based on 151 age in the treatment and control groups will help to decrease possible bias of enrolling 152 patients of more advanced age in one group. The propensity score was estimated via 153 logistic regression with no higher order or interaction terms. We conducted greedy 154 nearest neighbor one-to-one propensity score matching via the R package Matchlt.[15] 155 A caliper length of 0.2 multiplied by the standard deviation of the logit of the propensity 156 score was used.[16] Covariate mean balance was assessed via standardized mean 157 158 difference, with balance defined to be standardized mean difference < 0.1.[17] The matching criteria included ethnicity, age (categorical by decade), admission month 159 (continuous), sex, hypertension, lung disease, cancer, diabetes, obesity, smoking 160 161 status, and immunosuppression. Lung disease was defined as an underlying lung disorder that requires treatment including asthma, chronic obstructive pulmonary 162 163 disease, and interstitial lung disease. Immune suppression was defined as any 164 condition that results in suppression of immune responses including primary and 165 secondary immune deficiencies that result from treatment.

166 Statistical analysis

We modeled the primary outcome (time to hospital discharge) in a competing 167 risks framework, where in-hospital mortality is considered to be a competing risk.[18] All 168 study subjects were observed until time to in-hospital mortality or discharge, thus there 169 was no censoring. There were a small number of patients who were discharged from 170 the hospital, and later returned to the hospital and experienced in hospital mortality. The 171 172 analysis treated the eventual in-hospital mortality for these patients as unobserved. Time to discharge and time to inpatient mortality are displayed by the nonparametric 173 Aalen-Johansen curves. Inference is done via a Fine-Gray model for competing risks 174 with robust variance estimation for the propensity-matched cohorts (http://github.com). 175 In the Fine-Gray models, time to event is regressed on an indicator variable denoting 176 treatment status with no other covariates. 177

178 **Results:**

In our primary intention to treat analysis, 188 treatment and control subjects were 179 retained after propensity score matching for 376 total patients included in the trial 180 (Figure 1). The variance ratio was used to assess covariate variance balance, with 181 balance defined to be a variance ratio < 2.[19] Covariate balance was achieved after 182 propensity score matching for the intention to treat analysis (Figure 2). Propensity score 183 matching was also performed for the sub-analyses that limited the study population 184 185 based on time to infusion. Covariate balance was achieved for the 7 or fewer days to infusion analysis and was nearly, but not achieved for the 3 or fewer days to infusion 186 analysis (**Supplementary Figures 1&2**). Subject characteristics for the propensity 187 188 score matched intention to treat analysis are displayed in **Table 1**. Overall, the cohorts 189 enrolled represented the regional outbreak with higher proportion of older adult patients

(mean 58.9 years), male patients (56.9%), and 50.8% of patients in the study identified 190 as having a Hispanic ethnicity. In the total cohort, 67.2% of CCP-treated patients 191 identified as white or Caucasian, 15.7% identified as >1 race, 10.4% identified as black 192 or African American, and 4.8% identified as Asian. During the study, 38.3% of the 193 patients were enrolled during May of 2020 and 26.3% of the patients were enrolled 194 195 during July of 2020 (**Table 1**). Patients were matched based on month of enrollment due to the rapid changing treatment approaches throughout the pandemic. Comorbid 196 medical diagnoses including hypertension, diabetes mellitus, and obesity were found in 197 42-60% of the patients throughout the study and were matched at baseline for each 198 individual. 199

A total of 468 subjects, 226 in the treatment arm and 242 in the control arm, underwent propensity score matching (**Figure 1**). For the intention to treat analysis, 376 one-to-one matched CCP treatment and control subjects remained after propensity score matching. Analysis of patients who received CCP treatment at 7 days or less of hospitalization resulted in 358 total subjects after matching. For analysis of patients who received CCP treatment at 3 or fewer days of hospitalization, 322 total subjects remained after matching.

207 Overall, treatment of hospitalized COVID19 patients with CCP was associated 208 with a longer hospitalization calculated as a hazard ratio (0.67) for hospital discharge 209 favoring control COVID19 patients compared to CCP-treated patients (p=0.00053, 210 **Table 2**). As a secondary endpoint, there was no difference in inpatient mortality 211 (p=0.47). Column 4 displays the estimated hazard ratio of treatment status (compared 222 to control) on hospital discharge and inpatient mortality (**Table 2**). As these coefficients were estimated via Fine-Gray models, they should be interpreted as changes in the sub-distribution hazard function for each event type.[20] Values less than one indicate that treatment status reduces the hazard of the corresponding event. The estimated Aalen-Johansen incidence curves for hospital discharge and in-hospital mortality for each matched cohort show the probability of hospital discharge or inpatient mortality over time (**Figure 3**).

Analysis of COVID19 patients that received CCP treatment within 7 or 3 days of admission revealed no significant difference in hospital discharge or inpatient mortality in CCP treated patients compared to control patients (**Table 2**). The Aalen-Johansen curves for CCP-treated patients within 7 or 3 days of admission also show no significant difference in hospital discharge or inpatient mortality when compared to control COVID19 patients (**Supplementary Figures 3-6**).

Four patients had documented adverse events associated with CCP infusion. Three patients had allergic reactions with pruritus, rash, or urticaria, which resolved following treatment with acetaminophen and antihistamines. One patient developed a febrile transfusion reaction which improved with acetaminophen therapy. The transfusion was stopped in the patient after 60mL, and the patient was included in the analysis.

231 Discussion:

In this prospective, open-label, multicenter cohort-controlled study, we found that treatment of hospitalized COVID19 patients with CCP did not significantly improve time to hospital discharge or inpatient mortality compared to propensity matched controls.

Given that hospital discharge is considered a positive endpoint, the fact that treatment 235 reduces the hazard of hospital discharge is evidence that CCP treatment may have a 236 negative effect on the prognosis of study participants. However, this statistically 237 significant effect disappears in the two sub-analyses. This may be because study 238 participants who received convalescent plasma more than 7 days after hospital 239 240 admission differ systematically from the rest of the study population. For example, the patients that received CCP after 7 days may bias the treatment group to more severe 241 disease. We also found that CCP treatment status does not have a statistically 242 significant effect on the hazard of inpatient mortality. It would be difficult to detect an 243 effect of convalescent plasma treatment on the hazard of inpatient mortality in this study 244 given the relatively few number of inpatient deaths. 245

Previous, mostly non-controlled trials have suggested a potential benefit of CCP 246 therapy in hospitalized COVID19 patients. In a retrospective matched cohort study, 247 248 patients receiving CCP had decreased 7-day and 14-day mortality but no statistical difference in 28-day mortality. Similar to our study, the length of hospital stay was 249 increased in convalescent plasma group suggesting possible selection bias.[7] A 250 251 propensity matched study performed at Houston Methodist hospital from March 2020 through September 2020 showed a significant decrease in mortality for patients 252 transfused within 72 hours of admission with plasma containing anti-RBD IgG titer of > 253 1:1350. No mortality benefit was noted in patients who received RBD IgG titer of < 1: 254 1350 or were intubated at the time of admission.[6] In a cohort of 3082 patients who 255 received convalescent plasma through the Mayo Clinic initiated expanded access 256 protocol, non-mechanically ventilated patients who received high titer plasma had lower 257

relative risk for death as compared to patients in low titer group. However, this study didnot have a control group.[5]

260 Some randomized studies of CCP therapy in hospitalized COVID19 patients have shown no evidence of a clinical benefit. An open label RCT done earlier in the 261 pandemic in China enrolled 103 patients and had to be terminated early due to decline 262 in cases. This study did not show any benefit of convalescent plasma but was 263 264 underpowered for the intended end-points.[21] A smaller study performed in Argentina of older adults who received convalescent plasma within 72 hours of symptom onset 265 showed reduced risk of progression in patients receiving convalescent plasma.[22] In 266 the PLACID trial, an open label multicenter RCT in India, 2 units of convalescent plasma 267 was transfused. Neutralizing antibody was not found in 20% of the transfused plasma 268 and median neutralizing antibody ranged widely from 1:30- 1:240. In a smaller subgroup 269 of patients with pre-existing neutralizing antibody, no benefit was noted[23]. 270

The ConCOVID study was a randomized controlled trial comparing CCP with standard of care therapy. The study was discontinued early after enrollment of 86 patients (43 in each group) because a majority of enrolled patients had high titres of neutralizing antibody at the time of study enrollment and it was considered futile to continue further with the study. In this small subset of patients, no significant difference was noted in mortality or improvement in disease severity.[24]

277 Similar to prior studies, we found that convalescent plasma transfusion was well 278 tolerated with rare adverse events. [22, 25, 26] In our study, we did not document any 279 major transfusion reactions including transfusion-associated acute lung injury or

hemolytic reactions. Minor transfusion reactions were noted in 4 of 239 patients
(0.017%).

282 This study has several strengths including the multicenter design that included 16 academic and non-academic community hospitals throughout the Colorado front range 283 region. This resulted in recruitment of hospitalized COVID19 patients that represented 284 the demographics of the regional COVID19 pandemic with inclusion and analysis of a 285 diverse cohort of patients. The size of the cohorts analyzed, and the matched control 286 cohort were also strengths of the study. During this trial, there were no approved 287 standard therapies including remdesivir or dexamethasone at the time of study. 288 Weaknesses of the study include the open-label, non-randomized study design and lack 289 of a placebo control group. While all CCP was evaluated for presence of SARS-CoV2 290 specific antibody, many of the units were retrospectively tested through individual 291 regional plasma donation centers resulting in variability in the data. However, this 292 293 approach also represented CCP treatment and distribution in the community during the pandemic. 294

295

296 **Conclusion:**

The risks of CCP-treatment in hospitalized COVID19 patients are minimal, this study shows that treatment with CCP for hospitalized COVID19 patients provides no significant improvement in length of hospitalization or inpatient mortality. Ongoing multicenter, randomized controlled trials of CCP treatment for hospitalized and

- 301 outpatient COVID19 patients are critical to define a potential role for CCP therapy in the
- 302 SARS-CoV-2 epidemic.
- 303 Acknowledgements: This study was supported in part by grant provided through
- 304 Colorado Clinical and Translational Sciences Institute (CTSA Grant UL1 TR002535) to
- JDB. The study was also supported by institutional funds from University of Colorado
- 306 Anschutz Medical Campus, Department of Medicine to JDB.
- 307 References:
- Casadevall, A.; Dadachova, E.; Pirofski, L. A., Passive antibody therapy for infectious diseases.
 Nat Rev Microbiol 2004, 2, (9), 695-703.
- Casadevall, A.; Scharff, M. D., Return to the past: the case for antibody-based therapies in infectious diseases. *Clin Infect Dis* **1995**, 21, (1), 150-61.
- Zhang, J. S.; Chen, J. T.; Liu, Y. X.; Zhang, Z. S.; Gao, H.; Liu, Y.; Wang, X.; Ning, Y.; Liu, Y. F.; Gao,
 Q.; Xu, J. G.; Qin, C.; Dong, X. P.; Yin, W. D., A serological survey on neutralizing antibody titer of
 SARS convalescent sera. *J Med Virol* 2005, 77, (2), 147-50.
- Greenbaum, U.; Klein, K.; Martinez, F.; Song, J.; Thall, P. F.; Ramdial, J. L.; Knape, C.; Aung, F. M.;
 Scroggins, J.; Knopfelmacher, A.; Mulanovich, V.; Borjan, J.; Adachi, J.; Muthu, M.; Leung, C.;
 Medina, M. C.; Champlin, R.; Olson, A.; Alousi, A.; Rezvani, K.; Shpall, E. J., High levels of
 common cold coronavirus antibodies in convalescent plasma are associated with improved
 survival in COVID-19 patients. *medRxiv* 2021.
- Joyner, M. J.; Carter, R. E.; Senefeld, J. W.; Klassen, S. A.; Mills, J. R.; Johnson, P. W.; Theel, E. S.;
 Wiggins, C. C.; Bruno, K. A.; Klompas, A. M.; Lesser, E. R.; Kunze, K. L.; Sexton, M. A.; Diaz Soto, J.
- 322 C.; Baker, S. E.; Shepherd, J. R. A.; van Helmond, N.; Verdun, N. C.; Marks, P.; van Buskirk, C. M.;
 323 Winters, J. L.; Stubbs, J. R.; Rea, R. F.; Hodge, D. O.; Herasevich, V.; Whelan, E. R.; Clayburn, A. J.;
- Larson, K. F.; Ripoll, J. G.; Andersen, K. J.; Buras, M. R.; Vogt, M. N. P.; Dennis, J. J.; Regimbal, R.
 J.; Bauer, P. R.; Blair, J. E.; Paneth, N. S.; Fairweather, D.; Wright, R. S.; Casadevall, A.,
 Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. *N Engl J Med* 2021,
- 327 384, (11), 1015-1027.
- Salazar, E.; Christensen, P. A.; Graviss, E. A.; Nguyen, D. T.; Castillo, B.; Chen, J.; Lopez, B. V.;
 Eagar, T. N.; Yi, X.; Zhao, P.; Rogers, J.; Shehabeldin, A.; Joseph, D.; Masud, F.; Leveque, C.; Olsen,
 R. J.; Bernard, D. W.; Gollihar, J.; Musser, J. M., Significantly Decreased Mortality in a Large
 Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent
 Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
- 2) Spike Protein IgG. *The American journal of pathology* **2021,** 191, (1), 90-107.
- 3347.Shenoy, A. G.; Hettinger, A. Z.; Fernandez, S. J.; Blumenthal, J.; Baez, V., Early mortality benefit335with COVID-19 convalescent plasma: a matched control study. Br J Haematol 2021, 192, (4),336706-713.
- Group, R. C., Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a
 randomised controlled, open-label, platform trial. *Lancet* 2021.
- Li, L.; Zhang, W.; Hu, Y.; Tong, X.; Zheng, S.; Yang, J.; Kong, Y.; Ren, L.; Wei, Q.; Mei, H.; Hu, C.;
 Tao, C.; Yang, R.; Wang, J.; Yu, Y.; Guo, Y.; Wu, X.; Xu, Z.; Zeng, L.; Xiong, N.; Chen, L.; Wang, J.;

341		Man, N.; Liu, Y.; Xu, H.; Deng, E.; Zhang, X.; Li, C.; Wang, C.; Su, S.; Zhang, L.; Wang, J.; Wu, Y.;
342		Liu, Z., Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With
343		Severe and Life-threatening COVID-19: A Randomized Clinical Trial. Jama 2020.
344	10.	Simonovich, V. A.; Burgos Pratx, L. D.; Scibona, P.; Beruto, M. V.; Vallone, M. G.; Vazquez, C.;
345		Savoy, N.; Giunta, D. H.; Perez, L. G.; Sanchez, M. D. L.; Gamarnik, A. V.; Ojeda, D. S.; Santoro, D.
346		M.; Camino, P. J.; Antelo, S.; Rainero, K.; Vidiella, G. P.; Miyazaki, E. A.; Cornistein, W.;
347		Trabadelo, O. A.; Ross, F. M.; Spotti, M.; Funtowicz, G.; Scordo, W. E.; Losso, M. H.; Ferniot, I.;
348		Pardo, P. E.; Rodriguez, E.; Rucci, P.; Pasquali, J.; Fuentes, N. A.; Esperatti, M.; Speroni, G. A.;
349		Nannini, E. C.; Matteaccio, A.; Michelangelo, H. G.; Follmann, D.; Lane, H. C.; Belloso, W. H.;
350		PlasmAr Study, G., A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N
351		Engl J Med 2021, 384, (7), 619-629.
352	11.	Harris, P. A.; Taylor, R.; Thielke, R.; Payne, J.; Gonzalez, N.; Conde, J. G., Research electronic data
353		capture (REDCap)a metadata-driven methodology and workflow process for providing
354		translational research informatics support. J Biomed Inform 2009, 42, (2), 377-81.
355	12.	Pattanayak, C. W.; Rubin, D. B.; Zell, E. R., [Propensity score methods for creating covariate
356		balance in observational studies]. Rev Esp Cardiol 2011, 64, (10), 897-903.
357	13.	Rubin, D. B., Propensity score methods. Am J Ophthalmol 2010, 149, (1), 7-9.
358	14.	Ciceri, F.; Castagna, A.; Rovere-Querini, P.; De Cobelli, F.; Ruggeri, A.; Galli, L.; Conte, C.; De
359		Lorenzo, R.; Poli, A.; Ambrosio, A.; Signorelli, C.; Bossi, E.; Fazio, M.; Tresoldi, C.; Colombo, S.;
360		Monti, G.; Fominskiy, E.; Franchini, S.; Spessot, M.; Martinenghi, C.; Carlucci, M.; Beretta, L.;
361		Scandroglio, A. M.; Clementi, M.; Locatelli, M.; Tresoldi, M.; Scarpellini, P.; Martino, G.; Bosi, E.;
362		Dagna, L.; Lazzarin, A.; Landoni, G.; Zangrillo, A., Early predictors of clinical outcomes of COVID-
363		19 outbreak in Milan, Italy. <i>Clin Immunol</i> 2020, 217, 108509.
364	15.	Stuart, E. A., Matching methods for causal inference: A review and a look forward. Stat Sci 2010,
365		25, (1), 1-21.
366	16.	Austin, P. C., Optimal caliper widths for propensity-score matching when estimating differences
367		in means and differences in proportions in observational studies. Pharm Stat 2011, 10, (2), 150-
368		61.
369	17.	Zhang, Z.; Kim, H. J.; Lonjon, G.; Zhu, Y.; written on behalf of, A. M. E. BD. C. T. C. G., Balance
370		diagnostics after propensity score matching. Ann Transl Med 2019, 7, (1), 16.
371	18.	Brock, G. N.; Barnes, C.; Ramirez, J. A.; Myers, J., How to handle mortality when investigating
372		length of hospital stay and time to clinical stability. BMC Med Res Methodol 2011, 11, 144.
373	19.	Austin, P. C., Balance diagnostics for comparing the distribution of baseline covariates between
374		treatment groups in propensity-score matched samples. Stat Med 2009, 28, (25), 3083-107.
375	20.	Austin, P. C.; Fine, J. P., Practical recommendations for reporting Fine-Gray model analyses for
376		competing risk data. <i>Stat Med</i> 2017, 36, (27), 4391-4400.
377	21.	Li, L.; Zhang, W.; Hu, Y.; Tong, X.; Zheng, S.; Yang, J.; Kong, Y.; Ren, L.; Wei, Q.; Mei, H.; Hu, C.;
378		Tao, C.; Yang, R.; Wang, J.; Yu, Y.; Guo, Y.; Wu, X.; Xu, Z.; Zeng, L.; Xiong, N.; Chen, L.; Wang, J.;
379		Man, N.; Liu, Y.; Xu, H.; Deng, E.; Zhang, X.; Li, C.; Wang, C.; Su, S.; Zhang, L.; Wang, J.; Wu, Y.;
380		Liu, Z., Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With
381		Severe and Life-threatening COVID-19: A Randomized Clinical Trial. Jama 2020, 324, (5), 460-
382		470.
383	22.	Libster, R.; Perez Marc, G.; Wappner, D.; Coviello, S.; Bianchi, A.; Braem, V.; Esteban, I.;
384		Caballero, M. T.; Wood, C.; Berrueta, M.; Rondan, A.; Lescano, G.; Cruz, P.; Ritou, Y.; Fernandez
385		Vina, V.; Alvarez Paggi, D.; Esperante, S.; Ferreti, A.; Ofman, G.; Ciganda, A.; Rodriguez, R.;
386		Lantos, J.; Valentini, R.; Itcovici, N.; Hintze, A.; Oyarvide, M. L.; Etchegaray, C.; Neira, A.; Name,
387		I.; Alfonso, J.; Lopez Castelo, R.; Caruso, G.; Rapelius, S.; Alvez, F.; Etchenique, F.; Dimase, F.;
388		Alvarez, D.; Aranda, S. S.; Sanchez Yanotti, C.; De Luca, J.; Jares Baglivo, S.; Laudanno, S.;

389		Nowogrodzki, F.; Larrea, R.; Silveyra, M.; Leberzstein, G.; Debonis, A.; Molinos, J.; Gonzalez, M.;
390		Perez, E.; Kreplak, N.; Pastor Arguello, S.; Gibbons, L.; Althabe, F.; Bergel, E.; Polack, F. P.;
391		Fundacion, ICG., Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
392		N Engl J Med 2021, 384, (7), 610-618.
393	23.	Agarwal, A.; Mukherjee, A.; Kumar, G.; Chatterjee, P.; Bhatnagar, T.; Malhotra, P.; Collaborators,
394	25.	P. T., Convalescent plasma in the management of moderate covid-19 in adults in India: open
395		label phase II multicentre randomised controlled trial (PLACID Trial). <i>Bmj</i> 2020, 371, m3939.
396	24.	Gharbharan, A.; Jordans, C. C. E.; Geurtsvankessel, C.; den Hollander, J. G.; Karim, F.; Mollema, F.
397	24.	P. N.; Stalenhoef-Schukken, J. E.; Dofferhoff, A.; Ludwig, I.; Koster, A.; Hassing, RJ.; Bos, J. C.;
398		van Pottelberge, G. R.; Vlasveld, I. N.; Ammerlaan, H. S. M.; van Leeuwen-Segarceanu, E. M.;
399		Miedema, J.; van der Eerden, M.; Papageorgiou, G.; Boekhorst, P. t.; Swaneveld, F. H.; Katsikis, P.
400		D.; Mueller, Y.; Okba, N. M. A.; Koopmans, M. P. G.; Haagmans, B. H. G.; Rokx, C.; Rijnders, B. J.
401		A., Convalescent Plasma for COVID-19. A randomized clinical trial. <i>medRxiv</i> 2020 ,
402		2020.07.01.20139857.
403	25.	Joyner, M. J.; Bruno, K. A.; Klassen, S. A.; Kunze, K. L.; Johnson, P. W.; Lesser, E. R.; Wiggins, C. C.;
404	20.	Senefeld, J. W.; Klompas, A. M.; Hodge, D. O.; Shepherd, J. R. A.; Rea, R. F.; Whelan, E. R.;
405		Clayburn, A. J.; Spiegel, M. R.; Baker, S. E.; Larson, K. F.; Ripoll, J. G.; Andersen, K. J.; Buras, M. R.;
406		Vogt, M. N. P.; Herasevich, V.; Dennis, J. J.; Regimbal, R. J.; Bauer, P. R.; Blair, J. E.; van Buskirk, C.
407		M.; Winters, J. L.; Stubbs, J. R.; van Helmond, N.; Butterfield, B. P.; Sexton, M. A.; Diaz Soto, J. C.;
408		Paneth, N. S.; Verdun, N. C.; Marks, P.; Casadevall, A.; Fairweather, D.; Carter, R. E.; Wright, R. S.,
409		Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc
410		2020, 95, (9), 1888-1897.
411	26.	Joyner, M. J.; Wright, R. S.; Fairweather, D.; Senefeld, J. W.; Bruno, K. A.; Klassen, S. A.; Carter, R.
412		E.; Klompas, A. M.; Wiggins, C. C.; Shepherd, J. R.; Rea, R. F.; Whelan, E. R.; Clayburn, A. J.;
413		Spiegel, M. R.; Johnson, P. W.; Lesser, E. R.; Baker, S. E.; Larson, K. F.; Ripoll, J. G.; Andersen, K. J.;
414		Hodge, D. O.; Kunze, K. L.; Buras, M. R.; Vogt, M. N.; Herasevich, V.; Dennis, J. J.; Regimbal, R. J.;
415		Bauer, P. R.; Blair, J. E.; Van Buskirk, C. M.; Winters, J. L.; Stubbs, J. R.; Paneth, N. S.; Verdun, N.
416		C.; Marks, P.; Casadevall, A., Early safety indicators of COVID-19 convalescent plasma in 5000
417		patients. J Clin Invest 2020, 130, (9), 4791-4797.

- **Tables:**
- **Table 1:** Demographic Data for Propensity score matched control and CCP-treated COVID-19 patients.

	Control (n=188)	CCP-Treated (n=188)	Overall (n=376)
Age(Years)		· · · · · ·	
Mean (SD)	59.6 (16.8)	58.2(16.3)	58.9(16.5)
Median [Min, Max]	58.7[23.6,93.2]	58.6[19.3,91.9]	58.7[19.3,93.2]
Sex			
Male (%)	55.9%	58%	56.9%
Ethnicity			
Hispanic (%)	51.6%	50%	50.8%
Admission Month			
(2020)			
March	1 (0.5%)	1 (0.5%)	2 (0.5%)
April	32 (17%)	19 (10.1%)	51 (13.6%)
May	65 (34.6%)	79 (42.0%)	144 (38.3%)
June	14 (7.4%)	24 (12.8%)	38 (10.1%)
July	57 (30.3%)	42 (22.3%)	99 (26.3%)
August	19 (10.1%)	23 (12.2%)	42 (11.2%)
Comorbidities			
Hypertension (%)	47.9	45.2	46.5
Diabetes (%)	43.1	42.6	42.8
Obesity (%)	44.1	39.4	41.8
Immune	5.3	4.8	5.1
Suppression (%)			
Pre-existing Lung	11.2	12.8	12
Disease (%)			
Smoking Tobacco (%)	5.9	6.4	6.1

- **Table 2:** Number of patients in the matched treatment and control arms that experience primary
- 427 (hospital discharge) or secondary (inpatient mortality) outcomes.

Propensity Matched Cohorts								
Outcome Measure	Control	CCP Treated	Hazard Ratio	P-value				
	(n=188)	(n=188)	(CI)					
Hospital Discharge	165	161	0.67(0.54,0.85)	0.00053				
Inpatient Mortality	23	27	0.81(0.46,1.43)	0.47				
CCP Infusion within 7 days of Admission								
Outcome Measure	Control	CCP Treated	Hazard Ratio	P-value				
	(n=179)	(n=179)						
Hospital Discharge	158	155	0.84 (0.67,1.04)	0.11				
Inpatient Mortality	21	24	1.08 (0.59,1.97)	0.81				
CCP Infusion within 3 days of Admission								
Outcome Measure	Control	CCP Treated	Hazard Ratio	P-value				
	(n=161)	(n=161)						
Hospital Discharge	139	141	0.77 (0.42,1.42)	0.41				
Inpatient Mortality	22	20	0.83 (0.66,1.06)	0.13				

429 CCP = COVID19 Convalescent plasma, CI=confidence interval

432 Figure Legends


Figure 1. Flow-chart of patient enrollment and Propensity Score Matching.

Figure 2. Love plot showing covariate balance in full data set analysis before (red) and after (green)
 propensity score matching.

- 441 Figure 3. Cumulative incidence curves. A) Probability of hospital discharge over time in days. B)
- 442 Probability of inpatient mortality over time in days. Estimated using Aalen-Johansen analysis.


Adjusted

445 Figure 1:




449











Supplementary Figure 1. Love plot showing covariate balance in the 7 or fewer days to infusion analysis before and after propensity score matching.




Supplementary Figure 2. Love plot showing covariate balance in the 3 or fewer days to infusion analysis before and after propensity score matching.

Cumulative Incidence for Discharge




Supplementary Figure 3. Cumulative incidence curve for hospital discharge in the 7 or fewer days to infusion analysis. Estimated via Aalen-Johansen.




Cumulative Incidence for Mortality

Supplementary Figure 4. Cumulative incidence curve for mortality in the 7 or fewer days to infusion analysis. Estimated via Aalen-Johansen.

Cumulative Incidence for Discharge



Supplementary Figure 5. Cumulative incidence curve for hospital discharge in the 3 or fewer days to infusion analysis. Estimated via Aalen-Johansen.



Cumulative Incidence for Mortality

Supplementary Figure 6. Cumulative incidence curve for mortality in the 3 or fewer days to infusion analysis. Estimated via Aalen-Johansen.